326 related articles for article (PubMed ID: 11880489)
21. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
[TBL] [Abstract][Full Text] [Related]
22. Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials?
Bates GP; Hockly E
Curr Opin Neurol; 2003 Aug; 16(4):465-70. PubMed ID: 12869804
[TBL] [Abstract][Full Text] [Related]
23. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
[TBL] [Abstract][Full Text] [Related]
24. Caudate volume as an outcome measure in clinical trials for Huntington's disease: a pilot study.
Aylward EH; Rosenblatt A; Field K; Yallapragada V; Kieburtz K; McDermott M; Raymond LA; Almqvist EW; Hayden M; Ross CA
Brain Res Bull; 2003 Dec; 62(2):137-41. PubMed ID: 14638387
[TBL] [Abstract][Full Text] [Related]
25. Screening of therapeutic strategies for Huntington's disease in YAC128 transgenic mice.
Gil-Mohapel JM
CNS Neurosci Ther; 2012 Jan; 18(1):77-86. PubMed ID: 21501423
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease.
Ferrante RJ; Ryu H; Kubilus JK; D'Mello S; Sugars KL; Lee J; Lu P; Smith K; Browne S; Beal MF; Kristal BS; Stavrovskaya IG; Hewett S; Rubinsztein DC; Langley B; Ratan RR
J Neurosci; 2004 Nov; 24(46):10335-42. PubMed ID: 15548647
[TBL] [Abstract][Full Text] [Related]
27. Deficits in spermatogenesis but not neurogenesis are alleviated by chronic testosterone therapy in R6/1 Huntington's disease mice.
Hannan AJ; Ransome MI
J Neuroendocrinol; 2012 Feb; 24(2):341-56. PubMed ID: 21988129
[TBL] [Abstract][Full Text] [Related]
28. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease.
Schiefer J; Landwehrmeyer GB; Lüesse HG; Sprünken A; Puls C; Milkereit A; Milkereit E; Kosinski CM
Mov Disord; 2002 Jul; 17(4):748-57. PubMed ID: 12210870
[TBL] [Abstract][Full Text] [Related]
29. Lipoic acid improves survival in transgenic mouse models of Huntington's disease.
Andreassen OA; Ferrante RJ; Dedeoglu A; Beal MF
Neuroreport; 2001 Oct; 12(15):3371-3. PubMed ID: 11711888
[TBL] [Abstract][Full Text] [Related]
30. 2,4 DNP improves motor function, preserves medium spiny neuronal identity, and reduces oxidative stress in a mouse model of Huntington's disease.
Wu B; Jiang M; Peng Q; Li G; Hou Z; Milne GL; Mori S; Alonso R; Geisler JG; Duan W
Exp Neurol; 2017 Jul; 293():83-90. PubMed ID: 28359739
[TBL] [Abstract][Full Text] [Related]
31. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
[TBL] [Abstract][Full Text] [Related]
32. Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease.
Masuda N; Peng Q; Li Q; Jiang M; Liang Y; Wang X; Zhao M; Wang W; Ross CA; Duan W
Neurobiol Dis; 2008 Jun; 30(3):293-302. PubMed ID: 18395459
[TBL] [Abstract][Full Text] [Related]
33. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.
Yu ZX; Li SH; Evans J; Pillarisetti A; Li H; Li XJ
J Neurosci; 2003 Mar; 23(6):2193-202. PubMed ID: 12657678
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic effects of cystamine in a murine model of Huntington's disease.
Dedeoglu A; Kubilus JK; Jeitner TM; Matson SA; Bogdanov M; Kowall NW; Matson WR; Cooper AJ; Ratan RR; Beal MF; Hersch SM; Ferrante RJ
J Neurosci; 2002 Oct; 22(20):8942-50. PubMed ID: 12388601
[TBL] [Abstract][Full Text] [Related]
35. A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse.
Chopra V; Fox JH; Lieberman G; Dorsey K; Matson W; Waldmeier P; Housman DE; Kazantsev A; Young AB; Hersch S
Proc Natl Acad Sci U S A; 2007 Oct; 104(42):16685-9. PubMed ID: 17925440
[TBL] [Abstract][Full Text] [Related]
36. Cerebrovascular and blood-brain barrier impairments in Huntington's disease: Potential implications for its pathophysiology.
Drouin-Ouellet J; Sawiak SJ; Cisbani G; Lagacé M; Kuan WL; Saint-Pierre M; Dury RJ; Alata W; St-Amour I; Mason SL; Calon F; Lacroix S; Gowland PA; Francis ST; Barker RA; Cicchetti F
Ann Neurol; 2015 Aug; 78(2):160-77. PubMed ID: 25866151
[TBL] [Abstract][Full Text] [Related]
37. Spatiotemporal mapping of brain atrophy in mouse models of Huntington's disease using longitudinal in vivo magnetic resonance imaging.
Aggarwal M; Duan W; Hou Z; Rakesh N; Peng Q; Ross CA; Miller MI; Mori S; Zhang J
Neuroimage; 2012 May; 60(4):2086-95. PubMed ID: 22342677
[TBL] [Abstract][Full Text] [Related]
38. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice.
Morton AJ; Glynn D; Leavens W; Zheng Z; Faull RL; Skepper JN; Wight JM
Neurobiol Dis; 2009 Mar; 33(3):331-41. PubMed ID: 19130884
[TBL] [Abstract][Full Text] [Related]
39. Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model.
Cheng Y; Peng Q; Hou Z; Aggarwal M; Zhang J; Mori S; Ross CA; Duan W
Neuroimage; 2011 Jun; 56(3):1027-34. PubMed ID: 21320608
[TBL] [Abstract][Full Text] [Related]
40. Disease-modifying effects of ganglioside GM1 in Huntington's disease models.
Alpaugh M; Galleguillos D; Forero J; Morales LC; Lackey SW; Kar P; Di Pardo A; Holt A; Kerr BJ; Todd KG; Baker GB; Fouad K; Sipione S
EMBO Mol Med; 2017 Nov; 9(11):1537-1557. PubMed ID: 28993428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
